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Depending on the pathological findings, up to 60% of prostate cancer patients who
undergo radical prostatectomy (RP) will develop biochemical relapse and require further 
local treatment. Radiotherapy (RT) immediately after RP may potentially eradicate any 
residual localized microscopic disease in the prostate bed, and it is associated with
improved biochemical, clinical progression-free survival, and overall survival in patients 
with high-risk pathological features according to published randomized trials. Offering 
immediate adjuvant RT to all men with high-risk pathological factors we are over-treating 
around 50% of patients who would anyway be cancer-free, exposing them to unneces-
sary toxicity and adding costs to the health-care system. The current dilemma is, thus, 
whether to deliver adjuvant immediate RT solely on the basis of high-risk pathology, but 
in the absence of measurable prostate-specific antigen, or whether early salvage radio-
therapy would yield equivalent outcomes. Randomized trials are ongoing to definitely 
answer this question. Retrospective analyses suggest that there is a dose–response
favoring doses >70 Gy to the prostate bed. The evidence regarding the role of androgen 
deprivation therapy is emerging, and ongoing randomized trials are underway.
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iNTRODUCTiON
Prostate cancer is the most frequently diagnosed non-skin cancer in the western of world (1).
For such a frequent cancer, surprisingly, little certainties exist around its management.
After radical prostatectomy (RP), patients with high-risk pathological features, such as extracap-
sular prostatic extension (ECE), positive margins, seminal vesicle involvement (SVI), high Gleason 
score, and prostate-specific antigen (PSA) have a 40–70% risk of developing biochemical failure at 
some point in the future (2). Approximately, two-thirds of men with biochemical relapse will develop 
metastatic disease if left untreated (3).
Radiotherapy to the prostate loge has been used in both the adjuvant (ART) and the salvage (SRT) 
setting. Which of the two strategies is better remains an area of controversy despite the fact that 
there are three phase III randomized controlled trials that showed an improvement in biochemical 
progression-free survival (BPFS) when ART is administered as compared with RP alone (4–6). At 
the present time, there are no published randomized trials, and we dispose only of retrospective 
data for the use of SRT, making a direct comparison between ART and SRT flawed. While several 
trials comparing ART vs. SRT are on going, in this article, we summarize the available evidence on 
ART vs. SRT.
TABLe 1 | Randomized controlled trials comparing adjuvant postoperative radiotherapy vs. observation.
Reference N inclusion 
criteria
Dose 
(Gy)
Follow-up median  
(years)
10-year BPFS ART 
vs. NFT
10-year OS ART  
vs. NFT
10-year toxicity rate (%) ART  
vs. NFT
Thompson 
et al. (5)
425 pT3 60–64 12.7 52 vs. 26%
p < 0.001
74 vs. 66%
p = 0.023
GI, G3 = 3.3 vs. 0
GU, G3 17.8 vs. 9.5cN0/pN0
R0/R1
Bolla et al. (4) 1005 pT2–3 60 10.6 60 vs. 41% 77 vs. 81% GU > G2 = 21.3 vs. 13.5 (p = 0.003)
pN0 p < 0.0001 p = 0.2 GI > G2 = 2.5 vs. 1.9 (p = 0.47)
R0/R1
Wiegel et al. (6) 388 
(307)
pT3 60 9.3 56 vs. 35%
p < 0.0001
84 vs. 86%
p = 0.59
ART: GU, G3 = 1 patient, G2 = 2 
patients, GI, G2 = 2 patientspN0
R0/R1
PSA 0
BPFS, Biochemical progression-free survival; OS, overall survival; ART, adjuvant radiation therapy; NFT, no further therapy; GU, genitourinary; GI, gastro-intestinal; G, grade.
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ADJUvANT RADiATiON THeRAPY TRiALS
Three randomized controlled trials are summarized in Table 1 
showing the benefit of ART over RP alone. In these trials, ART 
was usually administered to the prostate loge within 4 months 
after RP (4–6). Two of the three randomized trials included 
patients with detectable PSA and therefore some patients actu-
ally received SRT, indirectly supporting its benefits over watchful 
waiting (4–6). With the introduction of ultrasensitive PSA, a new 
tool to detect low-volume disease became available, and therefore 
nowadays the term “adjuvant therapy” is used when the PSA is 
very low or undetectable (≤0.1  ng/ml) immediately or within 
4 months of RP. This highlights the temporal variation in practice 
patterns and limits the generalizability of the results of the rand-
omized trials to the contemporary population of prostate cancer 
patients. Nevertheless, these important studies provided evidence 
to support the use of postoperative RT in men with adverse 
pathologic features (ECE, SVI, or positive surgical margins). The 
question of whether all patients with the aforementioned adverse 
features should undergo immediate ART vs. initial observation 
with more selective – but early – SRT in the event of biochemical 
failure (using pre-defined PSA thresholds) remains a subject of 
controversy.
Certainly, men with prostate cancer will not necessarily die 
from the disease and even those who experience a biochemi-
cal failure will not necessarily become symptomatic from the 
disease (7).
Thus, the argument for postoperative radiotherapy (RT) is 
predicated on the assumption that some patients may have resid-
ual local disease of a potentially lethal phenotype after surgery 
and that the delivery of secondary local therapy may interrupt 
the natural history of disease and prevent progression to systemic 
disease. A basic question in this context is the extent to which 
this sequence of events – vs. the presence of occult metastases 
at surgery or the presence of a tumor that will never become 
symptomatic – characterizes the natural history of the disease.
eORTC 22911
The European Organization for Research and Treatment of 
Cancer (EORTC) recruited 1005 patients between 1992 and 
2001 to a randomized controlled trial (8). Patients with stage 
pT2–3, N0, M0 prostate cancer, and undetectable PSA defined as 
≤0.4 ng/ml with at least one adverse prognostic factor: positive 
surgical margins, ECE and/or SVI were randomized to receive 
ART with 60 Gy in 6 weeks to the prostate bed or observation. 
After a median follow-up of 10.6 years, the intervention arm was 
significantly superior based on BPFS (74 vs. 53%; HR 0.49, 95% CI 
0.41 to 0.59, p < 0.0001). The cumulative rate of loco-regional and 
any clinical failure was lower in the irradiated group (15 vs. 5%, 
p < 0.0001 and 19 vs. 9%, p < 0.0001, respectively). However, no 
significant benefit was observed in distant failures. Importantly, 
from the 265 patients in the observation arm who had biochemi-
cal progression 84% underwent an active treatment after progres-
sion (54.4% received pelvic radiotherapy, and 22.2% received 
androgen deprivation therapy-ADT). Salvage radiotherapy was 
administered to 23% of patients in the observation group. There 
was also a significant increase in late side effects of any type and 
any grade in the RT arm [10-year cumulative incidence 70.8% 
(66.6–75.0) vs. 59·7% (55.3–64.1); p = 0.001]. After 10 years of 
follow-up, improvements in clinical progression-free survival 
vanished, and overall survival (OS) was not improved (4).
SwOG 8794
From 1988 to 1997, the South West Oncology Study Group 
(SWOG) 8794 trial randomized 430 men with pT3, pN0, M0, ECE, 
positive margins, and/or SVI prostate cancer to ART (60–64 Gy) 
or observation (5, 9). There was no restriction on PSA level at 
enrollment. The primary endpoint was metastasis-free survival. 
Secondary endpoints were PSA relapse, recurrence-free survival, 
OS, and postoperative complications. With a median follow-up 
of 12.7 years, the study was positive for metastases-free survival 
favoring the RT arm (43 vs. 54%, HR 0.71, 95% CI 0.54–0.94; 
p = 0.016). Also the OS was improved significantly with ART (41 
vs. 52%, HR 0.72, 95% CI 0.55–0.96; p = 0.023).
Swanson et al. reported that the pattern of failure was local with 
22% of patients having a clinical local failure in the observation 
arm compared to 8% in the ART arm. An additional 11 patients 
in the observation arm had local and distant failures compared 
to 1 patient in the treated arm (10). The time to initiation of 
hormonal therapy differed in both groups with 21% of patients 
in the observation group having received ADT within 5 years post 
biochemical relapse vs. 10% of patients in the ART group (HR 
0.45; 95% CI 0.29–0.68, p < 0.001) (9).
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It has, however, been argued that the survival benefit may 
be due to hazard considering that the trial was not powered to 
detect an OS advantage as well as the fact that such clinical benefit 
was not found in the European Study (11). The most significant 
problem with the SWOG 8794 trial was the lack of disclosure 
of cause of death. There were 110 men (52%) who died in the 
observational group vs. 88 (41%) in the radiation group, but 
because of the long follow-up period it was not possible for the 
authors to ascertain if these patients died from metastatic prostate 
cancer or from competing hazards, which jeopardizes the impact 
of ART on OS.
Another observation from this trial is that the pre-radiation 
PSA level immediately after RP was predictive of subsequent 
outcome. For instance, for patients with an undetectable PSA 
(≤0.2 ng/ml), the 5-year PSA failure rate was 77% (very similar 
to the EORTC 22911 trial, 74%). However, patients with a post-
prostatectomy PSA between 0.2 and ≤1 ng/ml had a PSA failure 
rate of 34% at 5 years: this last group had an 8% increase in the 
risk of metastases indicating thus that RT with these PSA values 
is less efficient in eradicating larger tumor deposits (10). On the 
contrary, patients in the observation arm had a significant delay 
in initiating SRT. The median PSA at which patients were referred 
for salvage radiation was 1–1.5 ng/ml. A better comparison would 
have been made if patients in the observation arm had been 
offered RT at the first PSA failure.
ARO 96/02
The German study was the only real adjuvant study as the 
inclusion criteria permitted only patients with undetectable 
PSA. Those with persistently detectable PSA after surgery were 
declared as having progressive disease. The study recruited 
307 patients from 1997 to 2004. Eligible patients had pT3 pN0 
tumors with positive or negative margins. PSA failure was defined 
as two consecutive rises above undetectable. BPFS after 5 years 
was significantly improved with ART (72%, 95% CI 65–81%, vs. 
54%, 95% CI 45–63%, HR = 0.53, 95% CI 0.37–0.79, p = 0.0015). 
Despite a 10-year follow-up period, the study did not show any 
clinical benefit.
Grade 2 genitourinary and gastrointestinal toxicity in the RT 
arm were 2 and 1.4%, respectively (6).
wHO MiGHT BeNeFiT FROM iMMeDiATe 
POSTOPeRATive RADiOTHeRAPY?
In summary, the 3 studies included together over 1100 patients 
and had a substantial follow-up assessment that permits some 
conclusions: ART compared with watch and see strategy reduced 
by about 20% the risk of PSA relapse.
Van der Kwast et  al. reviewed about 50% of the pathology 
specimens in the EORTC 22911 trial, in particular with regard 
to positive surgical margins (12). After 5  years, immediate 
postoperative radiation was shown to prevent 191 events in 1000 
patients with positive margins vs. 88 events in 1000 patients with 
negative margins. The hazard ratio for immediate radiation was 
0.38 (95% CI 0.26–0.54) and 0.88 (95% CI 0.3–1.46) in the group 
with positive and negative margins, respectively. The finding of 
a significant association between margin status and adjuvant RT 
benefit was also reported in the subgroup analyses of ARO 96-02 
(6). The data indicate that patients with a pT3 tumor but negative 
margins may potentially benefit less or not at all from immediate 
ART. Exploratory analyses suggested that postoperative irradia-
tion might improve clinical progression-free survival in patients 
younger than 70 years old. Radiotherapy could have a detrimental 
effect in patients aged 70 years or older (13).
An important point to consider in the equation balance 
between ART and observation is that one-third of the patients 
in the wait and see arm of the randomized trials have received 
ADT within the first 5  years after biochemical progression. 
Therefore, the use of ART would lead to a diminished use of 
ADT. However, early initiation of ADT has not shown convinc-
ing benefit on OS (14, 15).
It is also important to note that the standard routine clinical 
practice has evolved since the publication of the three aforemen-
tioned randomized trials, and contemporary patients have access 
to ultra-sensitive PSA assays, consequently in modern clinical 
practice patients with an undetectable postoperative PSA level 
have a lower risk of relapse than those patients in the past and 
so less potential benefit from adjuvant immediate radiation. 
Ultra-sensitive PSA assays also lead to an earlier detection of 
biochemical relapse than clinical relapse, and this early detection 
may lead to an improvement in the efficacy of SRT as a therapeutic 
option. There is at the moment no consensus among clinicians on 
whether to use adjuvant or salvage radiotherapy, highlighting the 
need for offering these patients a randomized trial (16).
The potential for toxicity needs to be considered when coun-
seling patients for postprostatectomy RT, and this information 
provides support for more selective use.
SALvAGe RADiATiON THeRAPY
Salvage radiation therapy is supported by some clinicians based 
on the rationale that an elevated PSA in the postoperative setting 
or a delayed PSA rise is caused, at least in some patients, by the 
persistence of local disease. However, while the disease is localized 
to the surgical bed and curable with SRT, the presence of occult 
metastatic disease cannot be excluded. Certainly, adverse prog-
nostic factors in the pathology specimen such as ECE, positive 
margins, and SVI, support the concept of a local residual tumor 
and thus the use of salvage treatment (17). The lower the PSA at 
the time of salvage therapy, the better the outcome. Investigators 
have tried to use PSA cut-off points ranging from ≥0.1 to 10 ng/
ml (18–23). However, it should be noted that the relationship 
between pre-radiotherapy PSA and radiotherapy outcome is a 
continuum. In general, PSA recurrence rates have been reported 
to be higher when the PSA is ≥0.2 ng/ml (20, 21, 24). Other fac-
tors should also be considered such as the PSA doubling time as 
well as time to biochemical failure (25).
There have been multiple retrospective studies, which have 
looked at the clinical question of how adjuvant or salvage radiation 
affects local control, BPFS, and OS. Significant improvements in 
local control and BPFS have been observed in patients treated in 
the adjuvant or early adjuvant setting compared to those treated 
with late salvage therapy. The inherent caveat when comparing 
TABLe 2 | Selected series of salvage radiotherapy for PSA relapse after radical prostatectomy.
Reference N Comparison PSA pre-RT 
(ng/ml)
ADT 
(%)
Median 
follow-up 
(months)
BPFS (%) important 
prognositc 
factors
RT 
technique/
dose (Gy)
Grade 3 
toxicity (%)
Pfister (27) 737 Early salvage <0.5 6.7 51 71 PSA pre RT <0.2 2D/3D/IMRT 0.6–1.3
Trock (23) 160 SRT with PSA >0.2–22 Median 0.7 12 72 89 2D/3D/66.5
Swanson 
(26)
92 ART (n = 36) with 
postoperative PSA <0.4 vs. 
SRT (n = 56)
Median 1.5 0 146.4 35 vs. 25 GS >8 2D/3D/60–
70
NR
PSA >0.5
Trabulsi (22) 449 ART <12 months from 
surgery (n = 211)
<2 0 94 75 vs. 66 GS >8
Use of SRT
2D/3D/64 NR
SRT >12 months from 
surgery (n = 238)
Fossati (20) 955 Early salvage <0.5 0 57 82 PSA >0.2, >pT3, 
GS >7
2D/3D/66.6 NR
Cremers 
(19)
197 SRT (>6 months after RP) 45.7% with 
PSA <10 and 
53.8% with 
PSA > 10
0 40 59 GS >7, ECE, 
PSA >1ng/ml
3D/66 GU = 6
GI = 0.6
Jereczek-
Fossa (21)
431 ART <6 months after RP 
(n = 258)
ART 0–4
SRT 0.1–13.7
100 32 81 vs. 60.5 PSA >0.2
GS >6
Age <65
70 GI = 0.7
GU = 1.9
SRT >6 months after RT 
(n = 173)
Briganti (24) 390 PSA <0.3 vs. PSA >0.3 to 
<0.5
58 0 40.6 81.8 stage, GS, and 
positive SM
3D/66.2 NR
Siegmann 
(28)
301 SRT (median time to RT 
23 months)
0.28 0 30 78 vs. 61% for a PSA 
≤ or >0.28 ng/ml
pT3b, positive 
SM, pre-SRT 
PSA, PSA 
doubling time
3D/68.4 GU = 1.3
In 151 patients, SRT 
commenced at PSA 
≤0.28 ng/ml, in 150 at >0.28
Stephenson 
(2)
1540 Nomogram for disease 
progression after SRT
<0.5 to ≥0.5 0 53 PSA <0.5 = 48, PSA 
>0.51–1.00 = 40, 
PSA 1.01–1.50 = 28, 
PSA >1.50 = 18
GS, PSA 
doubling time, 
SM, ADT 
64.8 NR
GS, Gleason score; PSA, prostate-specific antigen; RT, radiotherapy; ADT, androgen deprivation therapy; BPFS, biochemical progression-free survival; ART, adjuvant radiation 
therapy; SRT, salvage radiation therapy; RP, radical prostatectomy; SM, surgical margins; GU, genitourinary; GI, gastro-intestinal; NR, not-reported; 2D, two dimensional 
radiotherapy; 3D, three-dimensional conformal radiotherapy.
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ARC vs. SRT in retrospective studies is that the patient receiving 
salvage treatments have in most of the cases confirmed recur-
rent disease, consequently the outcome of salvage radiation will 
always seem worse than ART (11). The 5-year BPFS rates were 
approximately 59–80% after ART (19–21) and 26–66% after 
salvage radiotherapy (22, 26). In some series, patients who had 
an undetectable PSA after SRT had a 75% chance to have an 
undetectable PSA at 3.5 years (6).
Table  2 summarizes the retrospective studies on SRT. It is 
clear from these retrospective studies that oncological outcomes 
are better when SRT is initiated at the lowest PSA values. Several 
studies showed that the biochemical relapse free survival can be 
>75% with pre-radiotherapy PSA of <0.5 ng/ml (24, 27).
A recent report by Pfister et  al. analyzed 10 retrospective 
reports on patients with early salvage radiotherapy (ESRT) 
(27). The term ESRT refers to patients with undetectable PSA 
after prostatectomy who have subsequent PSA rise ≤0.5 ng/ml. 
Significantly, increased cancer control rates have been reported 
with ESRT compared to late SRT. The mean 5-year biochemical 
relapse-free survival was 71% in a polled analysis of 886 patients 
treated with ESRT. However, no data on clinically outcomes such 
as metastasis-free survival or OS were available. Siegmann et al. 
(28) reported a BPFS of 83% at 2  years for patients with PSA 
≤0.2 ng/ml at the time of SRT compared to 61% for those with a 
PSA of ≥0.28 to ≤1 ng/ml, pointing out that further reducing the 
PSA cut-off point may increase biochemical outcomes.
The nomograms introduced by Stephenson et al. may help in 
the decision-making process (2). This nomogram was created 
from a pooled database of 1818 patients with a median follow-
up of 53 months after RT. Pre-surgical prognostic factors such 
as PSA, Gleason score, SVI, ECE, surgical margins, lymph node 
status, PSA at SRT, PSA doubling-time, time-to-recurrence, 
time from recurrence to radiation, radiation dose, and the use 
of ADT are considered to allow individualized risk stratification. 
Briganti et  al. (24) restricted the nomogram to patients with 
PSA <0.5 ng/ml and validated it with 200 bootstrap resamples 
demonstrating a good discrimination in outcome with a c-index 
of 0.74. By incorporating genomic tests into nomogram models, 
Den et al. (29) analyzed 188 patients with pT3 or positive margin 
prostate cancer looking at 22 pre-specified gene-signatures and 
reported an improvement in the Stephenson nomogram from 
a c-index of 0.70–0.80 for BPFS as well as distant metastases. 
Novel gene signatures describing the biology of prostate cancer 
progression have recently being summarized in a comprehensive 
TABLe 3 | Selected biomarkers tested in the postoperative setting.
Reference N Biomarker Assay Adverse prognostic factor for:
Den et al. (29) 188 (T3, margins positive) 22 genes Tumor-derived RNA Score ≥0.4, 6 vs. 23% probability of metastases for 
adjuvant vs. salvage RT
Parker et al. (33) 147 Ki-67 IHC BR after SRT
Cuzick et al. (31) 366 31 cell cycle progression genes Tumor-derived RNA BR after radical prostatectomy defined as PSA >0.3
Wu et al. (34) 270 32 genes Tumor derived real-time PCR BR after RP >20% risk if index score >3
Erho et al. (32) 546 22 genes of cell proliferation and 
mobility
Tumor-derived RNA BR after RP and metastatic progression
BR, Biochemical relapse; SRT, salvage radiation therapy; RP, radical prostatectomy; IHC, immunohistochemistry; RNA, ribonucleic acid; PCR, polymerase chain reaction.
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review (30). Table  3 describes biomarker studies in the 
 postoperative setting (31–34).
Certainly, when analyzing this data, one must consider that 
not all the patients treated with a PSA under 0.2  ng/ml will 
benefit clinically from SRT. The natural history of men with PSA 
relapses after RP is long: in the series described by Freedland 
et al., the median survival has not been reached after 16 years of 
follow-up. Patients at risk of prostate cancer death had shorter 
time to relapse, shorter PSA doubling times, and higher Gleason 
scores (7).
So far, only a few retrospective analyses have data on clinical 
significant endpoints. In the analysis by Boorjian et al., ART 
and SRT were independent predictors for biochemical and 
local control. In addition, SRT decreased the rate of systemic 
failures (35). Jereczek-Fossa et  al. reported on 431 patients 
treated between 1996 and 2006: 258 men received immediate 
RT for a rising PSA between 0.1 and 4 ng/ml vs. 173 men who 
received SRT >6  months after surgery for a rising PSA that 
was between 0.1 and 13.7  ng/ml. Interestingly, in this study 
>78% of patients had biopsy-confirmed prostate relapse at 
the time of SRT, and 10 patients had palpable disease in the 
prostate bed. After a median follow-up time of 48  months, 
failure-free survival including BPFS and clinical failure was 
significantly longer in the immediate RT group (79.8 vs. 60.5%, 
p <  0.0001). In multivariate analysis, pre-radiotherapy PSA 
≥0.2 ng/ml (p < 0.001) correlated with worst clinical outcome 
highlighting the more advanced tumors included in the SRT 
group (21). Swanson et  al. reported a series of 92 patients 
referred to SRT for a rising PSA level at the time of referral 
from 0.1 to 30.5 ng/ml (median 1.5 ng/ml). The median time 
from surgery to radiation was 2.1 years (range 0.3–7.4 years). 
After a median follow-up time of 12.2 years, the 5- and 10-year 
BPFS was 35 and 26%, respectively, and OS was 86 and 67%, 
respectively. The median biochemical-free survival after SRT 
was 2.3 years (26).
The benefits of SRT should always be balanced against the 
morbidity of the therapy. Many large retrospective series assess-
ing oncological outcomes after SRT did not include long-term 
toxicity data. In a retrospective series of 742 patients who 
underwent ART or SRT, the incidence of acute toxicity grade 2 
or more was 19% after ART and 17% after SRT. The incidence 
of grade 3 toxicity was 8 and 6%, respectively. No differences in 
grade 2 or more late toxicity were observed. However, there were 
slightly more grade 3 late toxicity events in the ART group (12.2 
vs. 10%) (36).
SALvAGe RADiOTHeRAPY AND 
ANDROGeN DePRivATiON THeRAPY
GETUG-AFU 16 was the first randomized trial comparing SRT 
vs. SRT and short ADT as salvage treatment for biochemical 
recurrent prostate cancer after radical prostatectomy and was 
presented in abstract form at the American Association of Clinical 
Oncology (ASCO) 2015 Annual Meeting. The trial randomized 
743 patients most of them having high intermediate risk features 
(pT2ac: 54%, pT3ac: 46%, gleason >6: 76%, positive margins: 
51%, seminal vesicles’ involvement 13%, and PSA doubling time 
at relapse was >6 months in 74%). The 5-year PFS was 62.1% (CI 
95%: 57–67) vs. 79.6% (CI 95%: 75–84) for SRT and SRT + ADT, 
respectively (p <  0.0001). The 5-year OS was 94.8% for RT vs. 
96.2% for SRT + ADT (p = 0.18). Cause of death was progres-
sive disease in 2.1% of the patients on SRT arm vs. 0.8% in the 
SRT + ADT arm. Acute toxicities occurred more frequently in 
SRT + ADT arm (89 vs. 79%). This trial will require longer follow-
up to see if the benefits observed in progression-free survival 
translate into the same OS benefit (37).
A recent phase I/II study evaluated 75 patients with PSA 
relapse after RP who were treated with SRT followed by 2-year 
ADT. Androgen ablation therapy started within 1 month after 
the completion of SRT. The study used a PSA rise above 0.2 ng/
ml with two consecutive increases over a minimum of 3 months 
as the definition of PSA relapse post-therapy. All achieved 
initially complete PSA response (<0.2 ng/ml) with the protocol 
treatment. With the median follow-up of 6.4 years (range: 2–9.8) 
from SRT, the study reported that a relapse-free rate including 
the freedom from PSA relapse was 91.5% at 5 years and 78.6% at 
7 years, and OS rate was 93.2% at both 5 and 7 years (17). Some 
retrospective data suggest that adding ADT to SRT increases 
patient’s BPFS outcome. Tiguert et al. published a 5-year BPFS 
rate of 50% for 81 patients treated with 3 months of neoadjuvant 
ADT followed by SRT (38). In another series of 115 patients, 
45 patients received 3  months of ADT followed by SRT and 
70 patients were treated with SRT alone. The 4-year BPFS was 
better for patients treated with neoadjuvant ADT (59 vs. 39%) 
(39). King compared treatment outcomes between SRT plus 
4-month ADT (2-months before and 2-months during RT) 
and SRT alone in a retrospective study of 122 patients (40). 
A 5-year BPFS rate was better for those treated with SRT plus 
4-month ADT than for those receiving SRT alone (57 vs. 31%). 
Taylor et al. (41) reported on 35 out of 71 patients treated with 
adjuvant ADT for a median duration of 24  months. After a 
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median follow-up of 39 months, the 5-year BPFS rate was 81% 
for patients receiving adjuvant ADT, compared with 54% for 
those treated with SRT alone.
On the other hand, Trock et al. published a retrospective analy-
sis of 635 men treated from 1982 to 2004 who received no SRT 
(n = 397) with a median PSA level of 9.6 ng/ml, SRT (n = 160) 
with a median PSA level of 8.3 ng/ml, and SRT combined with 
ADT (n = 78) who had a median PSA level of 7.7 ng/ml (23). The 
groups were otherwise not well balanced regarding pathological 
and clinical factors and patients who had SRT combined with 
ADT had a shorter time to recurrence, shorter PSA doubling 
time, and a higher PSA level at the time RT was initiated. The 
primary outcome was prostate cancer-specific survival defined 
from time to recurrence to death. SRT alone was associated 
with a significant threefold increase in prostate cancer-specific 
survival relative to those who received no further treatment (HR 
0.34, 95% CI 0.17–0.69, p = 0.003). In this study, the addition of 
ADT was not associated with any additional increase in prostate 
cancer-specific survival. Notably, patients in the no-SRT group 
had a much higher prevalence of positive pelvic lymph nodes at 
recurrence.
RADiOLOGiCAL ASSeSSMeNT
It should also be noted that patients undergoing SRT should be 
correctly staged. However, conventional imaging investigations 
such as bone scan and computed tomography of the chest, 
abdomen, and pelvis have been very insensitive for patients with 
biochemical-relapsed prostate cancer after RP. Nevertheless, we 
perform these tests in our routine clinical practice because the 
detection of any distant metastasis obviates the need for local 
salvage treatment. Cher et al. reported in a series of 93 patients 
with PSA relapse that the probability of a positive bone scan was 
<5%, unless a PSA level was above 40 ng/ml (42).
Similarly, the sensitivity of abdominopelvic CT scans is 
limited when PSA levels are low. Okotie reported that when the 
PSA was <10 ng/ml, the probability of a positive CT scan was 
non-existent (43). However, the use of MRI has enabled clinicians 
to assess the prostate bed more accurately. Miralbell et al. showed 
that MRI was capable of documenting a recurrent or residual 
disease in the setting of PSA levels ranging from 0.05 to 13.3 ng/
ml (median: 0.87), typically in the inferior and posterior region 
of the vesicourethral anastomosis (44).
The use of conventional positron emission tomography (PET) 
tracers such as 18F-fluorodeoxyglucose (FDG) is of no help in 
prostate cancer due to a low glycolysis rate and the renal excretion 
of the isotope into the bladder, enabling any local uptake.
In this context, recent studies showed that for patients with 
biochemical recurrence choline PET/CT may visualize the site 
of recurrence earlier and with higher accuracy than conventional 
imaging modalities. Rinnab et al. reported that 11C-choline PET/
CT had a sensitivity of 89% and a specificity of 40% for patients 
with post-RP PSA levels <2.5 ng/ml (45). A higher PSA level, PSA 
velocity, and PSA doubling time are predictive factors for having 
a positive 11C-choline PET/CT (46). In a series of 21 patients 
with post-RP PSA relapse (median PSA: 1.98 ng/ml), 11C-choline 
PET/CT improved the detection of lymph node metastases that 
were subsequently confirmed by histological assessment in 19 of 
the 21 patients (90%) (47). On a nodal site-based analysis, it was 
estimated that the sensitivity, specificity, positive predictive value, 
negative predictive value, and accuracy of 11C-choline PET/CT 
was 64, 90, 86, 72, and 77%, respectively (48).
The information gained with PET/CT in this clinical setting 
has the potential to change disease management. In a recent clini-
cal series reported by Alongi et al., 15 patients with biochemical 
recurrence after HIFU therapy and a median pre-RT PSA of 
5.2  ng/ml (range: 2–64.2) underwent 11 C-choline PET/CTs, 
documenting intra-prostatic-only failure and allowing a better 
tailored salvaged treatment using volumetric modulated arc 
therapy (VMAT) (49).
Conversely, a recent study raised some doubt over the sensi-
tivity of PET/CT in the clinical setting of low PSA levels. Vees 
et al. reported, in a series of 20 patients with post-RP PSA levels 
≤1  ng/ml, that only 11 were found to have a positive PET/CT 
using either 18F-choline or 11C-acetate (50).
This highlights the fact that PET/CT often remains negative in 
early relapse situations when PSA levels are still very low (<1 ng/
ml). Unfortunately, these levels are the “window” where ESRT will 
be most effective. Other tracers such as Ga-68-Prostate Specific 
Membrane Antigen (PSMA) are emerging in recent literature 
with preliminary promising results (51, 52).
RADiATiON DOSe, TeCHNiQUe, AND THe 
eFFeCT OF DOSe eSCALATiON
Traditionally, the three randomized trials for ART used 
60–65 Gy typically with 3D simulation (4–6). In some cases, the 
treatment volumes were typically very generous being described 
as approximately 10 cm × 10 cm in the anterior–posterior fields 
with the inferior border at the ischial tuberosities. The lateral 
fields extended from the anterior aspect of the pubic symphysis 
and split the rectum posteriorly (8). In 3-Dimensional Conformal 
Radiation Therapy (3D-CRT), the target volume should include 
the bladder neck (pulled into the prostate bed), periprostatic 
tissues/clips, and the seminal vesicle bed (including any semi-
nal vesicle remnants if present). Inferiorly, the vesicourethral 
anastomosis should be included. The anastomosis is the most 
frequent area of positive prostate biopsies (53, 54). By placing 
the inferior field edge at the top of the bulb of the penis and 
adding a margin for uncertainties, there should be adequate 
coverage. Laterally, the field should extend to about the medial 
aspect of each obturator internus muscle. Although the rectum 
is a landmark posteriorly, and its movement has been a matter 
of possible target missing, for this reason, a generous margin 
posteriorly is recommended in international guidelines (55). The 
superior margin is more subjective and should be guided by the 
extent of disease at the prostate base and whether the seminal 
vesicles are involved (56).
In accordance with the well-described dose-escalation trials 
for primary RT of localized prostate cancer, it has recently been 
proposed that dose intensification either for SRT or ART would 
be more effective in terms of cancer control (57).
Also, it has been suggested that each Gy increase in total 
dose may improve the BPFS by more than 3% (58). Therefore, 
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a total dose toward 70  Gy might be considered in the salvage 
situation, when the risk of severe toxicity can be minimized by 
using modern radiation techniques. In the absence of results from 
randomized trials, the potentially improved local tumor control 
by a higher RT dose should be carefully weighted up against pos-
sibly increased toxicity.
An increase in the RT dose will certainly increase grade 
3 or more late toxicity. In a retrospective study where 70  Gy 
were administered using intensity-modulated radiation therapy 
(IMRT) to the prostate bed, urinary incontinence reached 13% 
and erectile dysfunction 26% (59). With higher doses of IMRT 
76 Gy, the genitourinary and intestinal toxicity increased to 22 
and 8% of the patients, respectively (60).
Although theoretical assumptions might claim a ben-
efit in escalating the RT dose, a randomized trial is needed to 
definitely answer this question. The Swiss Group for Clinical 
Cancer Research (SAKK) conducted a randomized controlled 
international trial comparing SRT with 64 vs. 70  Gy without 
ADT in patients with prostate cancer and biochemical relapse 
after RP (SAKK 09/10, NCT01272050). The trial included men 
≤75 years with pT2–3 N0 R0-1, with a PSA of at least ≥0.1 ng/ml 
and above but not higher than 2 ng/ml. Patients with evidence 
of macroscopic recurrence or metastatic disease were excluded. 
The primary endpoint was freedom from biochemical progres-
sion including a PSA of ≥0.4 ng/ml and above and/or clinical 
failure. The trial included quality of life analysis, quality assur-
ance of RT, and a central pathology review. Three-dimensional 
conformal or IMRT were allowed per protocol. Three hundred 
and forty-four patients were randomized. The 13% grade 2 acute 
genitourinary toxicity and 0.6% grade 3 acute intestinal toxicity 
with 64 Gy were reported in comparison to 16.6% grade 2 and 
1.7% grade 3 genitourinary toxicity with 70 Gy (p = 0.2). The 
16% grade 2 acute intestinal toxicity and 0.6% grade 3 acute 
intestinal toxicity with 64 Gy were reported in comparison to 
15.4% grade 2 and 2.3% grade 3 with 70 Gy (p = 0.8). Patients 
who received 70 Gy reported a more pronounced and clinically 
relevant genitourinary toxicity (mean difference in change score 
between arms, 3.6; p =  0.02) (61). Considering that this is an 
early report on toxicity, long-term toxicity as well as efficacy 
analysis is still pending.
CURReNT PHASe iii STUDieS  
FOR PSA ReLAPSe
The Radiation Therapy Oncology Group completed a phase III 
clinical trial (RTOG 9601) comparing ART with SRT (64.6 Gy 
in 36 fractions) plus 2 years of a high dose bicalutamide (150 mg 
per day) for patients with post-RP PSA relapse. The study group 
included patients with PSA levels from 0.2 to 4.0 ng/ml with pros-
tate tumors classified as either pT2pN0 and a positive surgical 
margin or pT3pN0. The study closed in 2003 after accruing a total 
of 840 patients. Its final publication is pending at present. A recent 
presentation at the American Society for Radiation Oncology 
(ASTRO) reported that at a median follow-up of 12.6 years, there 
was an improvement in OS of 82% for the RT plus ADT vs. 78% 
for the RT plus placebo patients; with a hazard ratio of 0.75 (95 
percent CI: 0.58–0.98) with a two-sided p-value =  0.036. Data 
indicated that the addition of ADT decreased the rate of death by 
prostate cancer and decreased the risk of the cancer metastasiz-
ing. The 12-year incidence of prostate cancer centrally-reviewed 
deaths was 2.3% for the RT plus ADT group, compared to 7.5% 
for the radiation plus placebo group (p <  0.001). At 12  years, 
the cancer had metastasized in 51 patients (14%) in the RT plus 
ADT group, compared to 83 patients (23%) in the radiation plus 
placebo group (p < 0.001). Additionally, late grade 3 and grade 
4 bladder and bowel side effects were similar in both groups, 
whereas 70% of men in the RT plus ADT reported swelling of 
the breasts, compared to 11% from the radiation plus placebo 
group (62).
Currently, the RTOG is conducting another phase III, three-
arm, study (RTOG 0534) to examine the potential benefit of 
adding 4–6 months of ADT to SRT and to address a potential 
role of treating pelvic lymph nodes. The United Kingdom is 
conducting a phase III study called RADICALS (Radiotherapy 
and Androgen Deprivation in Combination After Local Surgery), 
and part of this study is to assess the benefit of adding 6-months 
or 24-months of ADT to SRT. A French group is conducting a 
phase III study comparing SRT with SRT plus 6-months of ADT 
(Clinical Trials Gov. Identifier: NCT00423475). Unfortunately, 
the EORTC 22043, a two-arm phase III trial, which compared 
6 months of ADT concomitant to ART, closed in 2014 due to lack 
of patient accrual.
CONCLUSiON
Radiotherapy represents a curative approach to treat prostate 
cancer in patients with postoperative detectable PSA. However, its 
efficacy is affected by the presence of adverse clinical/pathologi-
cal prognostic factors. In this context, a patient with PSA relapse 
after RP represents a clinical dilemma. Treatment decisions have 
been jeopardized by a variety of retrospective trials that have 
used different postoperative PSA cut-off points and the lack of 
clear evidence demonstrating which therapeutic attitude is best, 
particularly in prolonging the patient’s life without significant 
side effects. The use of ART over observation has been proven 
to prolong BPFS in phase III randomized trials, but its benefit in 
prolonging OS has also been questioned. The challenge of manag-
ing these patients in current clinical practice will be solved in the 
near future when the results of different on-going randomized 
trials become available.
AUTHOR CONTRiBUTiONS
FH and DB both collected the data and drafted the manuscript. 
DB approved the submitted version of the manuscript.
ACKNOwLeDGMeNTS
We thank our colleagues from the urology and radiotherapy 
units (Patrice Jichslinski, Massimo Valerio, Yannick Cerantola, 
Thomas Tawadros, Berardino De Bari, Jean Bourhis, and Caroline 
Codeluppi) for the excellent multidisciplinary patient care. We 
are grateful to Julia Styles and Laurence Benoit for their help in 
manuscript preparation.
8Herrera and Berthold Who Might Benefit from Immediate Postoperative Radiotherapy?
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 117
ReFeReNCeS
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et  al. 
Cancer incidence and mortality worldwide: sources, methods and major pat-
terns in GLOBOCAN 2012. Int J Cancer (2015) 136(5):E359–86. doi:10.1002/
ijc.29210 
2. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, 
et al. Predicting the outcome of salvage radiation therapy for recurrent pros-
tate cancer after radical prostatectomy. J Clin Oncol (2007) 25(15):2035–41. 
doi:10.1200/JCO.2006.08.9607 
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. 
Natural history of progression after PSA elevation following radical prostatec-
tomy. JAMA (1999) 281(17):1591–7. doi:10.1001/jama.281.17.1591 
4. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. 
Postoperative radiotherapy after radical prostatectomy for high-risk prostate 
cancer: long-term results of a randomised controlled trial (EORTC trial 22911). 
Lancet (2012) 380(9858):2018–27. doi:10.1016/S0140-6736(12)61253-7 
5. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. 
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly 
reduces risk of metastases and improves survival: long-term followup of 
a randomized clinical trial. J Urol (2009) 181(3):956–62. doi:10.1016/j.
juro.2008.11.032 
6. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et  al. Phase 
III postoperative adjuvant radiotherapy after radical prostatectomy compared 
with radical prostatectomy alone in pT3 prostate cancer with postoperative 
undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin 
Oncol (2009) 27(18):2924–30. doi:10.1200/JCO.2008.18.9563 
7. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, 
Walsh  PC, et  al. Risk of prostate cancer-specific mortality following bio-
chemical recurrence after radical prostatectomy. JAMA (2005) 294(4):433–9. 
doi:10.1001/jama.294.4.433 
8. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, 
et  al. Postoperative radiotherapy after radical prostatectomy: a randomised 
controlled trial (EORTC trial 22911). Lancet (2005) 366(9485):572–8. 
doi:10.1016/S0140-6736(05)67101-2 
9. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, 
et  al. Adjuvant radiotherapy for pathologically advanced prostate cancer: 
a randomized clinical trial. JAMA (2006) 296(19):2329–35. doi:10.1001/
jama.296.19.2329 
10. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, 
et  al. Predominant treatment failure in postprostatectomy patients is local: 
analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 
25(16):2225–9. doi:10.1200/JCO.2006.09.6495 
11. Parker CC, Sydes MR. Postoperative radiotherapy after radical prostatec-
tomy: let’s work together to tackle the known unknowns. Eur Urol (2014) 
65(6):1044–5. doi:10.1016/j.eururo.2013.09.035 
12. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, 
Da Pozzo L, et al. Identification of patients with prostate cancer who benefit 
from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 
(2007) 25(27):4178–86. doi:10.1200/JCO.2006.10.4067 
13. Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L, 
et al. Patients at high risk of progression after radical prostatectomy: do they 
all benefit from immediate post-operative irradiation? (EORTC trial 22911). 
Eur J Cancer (2005) 41(17):2662–72. doi:10.1016/j.ejca.2005.06.024 
14. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. 
Immediate or deferred androgen deprivation for patients with prostate cancer 
not suitable for local treatment with curative intent: European Organisation 
for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 
(2006) 24(12):1868–76. doi:10.1200/JCO.2005.04.7423 
15. Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, 
Knonagel H, et al. Differences in time to disease progression do not predict 
for  cancer-specific survival in patients receiving immediate or deferred 
androgen-deprivation therapy for prostate cancer: final results of EORTC ran-
domized trial 30891 with 12 years of follow-up. Eur Urol (2014) 66(5):829–38. 
doi:10.1016/j.eururo.2013.07.024 
16. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy 
following radical prostatectomy for prostate cancer. Cochrane Database Syst 
Rev (2011) 12:CD007234. doi:10.1002/14651858.CD007234.pub2 
17. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, et al. 
Prospective study evaluating postoperative radiotherapy plus 2-year andro-
gen suppression for post-radical prostatectomy patients with pathologic T3 
disease and/or positive surgical margins. Int J Radiat Oncol Biol Phys (2009) 
75(2):407–12. doi:10.1016/j.ijrobp.2008.12.049 
18. Budiharto T, Perneel C, Haustermans K, Junius S, Tombal B, Scalliet P, et al. 
A multi-institutional analysis comparing adjuvant and salvage radiation therapy 
for high-risk prostate cancer patients with undetectable PSA after prostatec-
tomy. Radiother Oncol (2010) 97(3):474–9. doi:10.1016/j.radonc.2010.07.008 
19. Cremers RG, van Lin EN, Gerrits WL, van Tol-Geerdink JJ, Kiemeney LA, 
Vergunst H, et  al. Efficacy and tolerance of salvage radiotherapy after 
radical prostatectomy, with emphasis on high-risk patients suited for 
adjuvant radiotherapy. Radiother Oncol (2010) 97(3):467–73. doi:10.1016/j.
radonc.2010.05.023 
20. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, et al. 
Assessing the optimal timing for early salvage radiation therapy in patients 
with prostate-specific antigen rise after radical prostatectomy. Eur Urol (2015) 
4:728–33. doi:10.1016/j.eururo.2015.10.009
21. Jereczek-Fossa BA, Zerini D, Vavassori A, Fodor C, Santoro L, Minissale A, 
et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated 
with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys (2009) 
74(1):115–25. doi:10.1016/j.ijrobp.2008.07.057 
22. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, 
et al. A multi-institutional matched-control analysis of adjuvant and salvage 
postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 
72(6):1298–302. doi:10.1016/j.urology.2008.05.057 discussion 302–4 
23. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. 
Prostate cancer-specific survival following salvage radiotherapy vs observa-
tion in men with biochemical recurrence after radical prostatectomy. JAMA 
(2008) 299(23):2760–9. doi:10.1001/jama.299.23.2760 
24. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, et al. 
Prediction of outcome following early salvage radiotherapy among patients 
with biochemical recurrence after radical prostatectomy. Eur Urol (2014) 
66(3):479–86. doi:10.1016/j.eururo.2013.11.045 
25. D’Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, 
et al. Adjuvant versus salvage radiation therapy for prostate cancer and the 
risk of death. BJU Int (2010) 106(11):1618–22. doi:10.1111/j.1464-410X. 
2010.09447.x 
26. Swanson GP, Du F, Michalek JE, Hermans M. Long-term follow-up and risk 
of cancer death after radiation for post-prostatectomy rising prostate- specific 
antigen. Int J Radiat Oncol Biol Phys (2011) 80(1):62–8. doi:10.1016/j.
ijrobp.2010.01.043 
27. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, et al. Early 
salvage radiotherapy following radical prostatectomy. Eur Urol (2014) 
65(6):1034–43. doi:10.1016/j.eururo.2013.08.013 
28. Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, et al. 
Salvage radiotherapy after prostatectomy  –  what is the best time to treat? 
Radiother Oncol (2012) 103(2):239–43. doi:10.1016/j.radonc.2011.10.024 
29. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, et  al. 
Genomic classifier identifies men with adverse pathology after radical pros-
tatectomy who benefit from adjuvant radiation therapy. J Clin Oncol (2015) 
33(8):944–51. doi:10.1200/JCO.2014.59.0026 
30. Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG. Mechanistic Insights 
into Molecular Targeting and Combined Modality Therapy for Aggressive, 
Localized Prostate Cancer. Front Oncol (2016) 6:24. doi:10.3389/
fonc.2016.00024 
31. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. 
Prognostic value of an RNA expression signature derived from cell cycle pro-
liferation genes in patients with prostate cancer: a retrospective study. Lancet 
Oncol (2011) 12(3):245–55. doi:10.1016/S1470-2045(10)70295-3 
32. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery 
and validation of a prostate cancer genomic classifier that predicts early 
metastasis following radical prostatectomy. PLoS One (2013) 8(6):e66855. 
doi:10.1371/journal.pone.0066855 
33. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, et al. 
Evaluation of ki-67 staining levels as an independent biomarker of biochemi-
cal recurrence after salvage radiation therapy for prostate cancer. Int J Radiat 
Oncol Biol Phys (2009) 75(5):1364–70. doi:10.1016/j.ijrobp.2008.12.061 
9Herrera and Berthold Who Might Benefit from Immediate Postoperative Radiotherapy?
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 117
34. Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, et al. Development 
and validation of a 32-gene prognostic index for prostate cancer progression. 
Proc Natl Acad Sci U S A (2013) 110(15):6121–6. doi:10.1073/pnas.1215870110 
35. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, 
Blute  ML, et  al. Long-term risk of clinical progression after biochemical 
recurrence following radical prostatectomy: the impact of time from surgery 
to recurrence. Eur Urol (2011) 59(6):893–9. doi:10.1016/j.eururo.2011.02.026 
36. Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A, 
et  al. Clinical factors predicting late severe urinary toxicity after postoper-
ative radiotherapy for prostate carcinoma: a single-institute analysis of 742 
patients. Int J Radiat Oncol Biol Phys (2012) 82(1):191–9. doi:10.1016/j.ijrobp. 
2010.09.027 
37. Carrie C, Hasbini A, De Laroche G, Habibian M, Richaud P, Guérif S, et al. 
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as 
salvage treatment for biological relapse (BR) after radical prostatectomy (RP): 
results of the GETUG-AFU 16 phase III randomized trial – NCT00423475. 
J Clin Oncol (2015) 33(15–Suppl):5006. 
38. Tiguert R, Rigaud J, Lacombe L, Laverdiere J, Fradet Y. Neoadjuvant hormone 
therapy before salvage radiotherapy for an increasing post-radical prostatec-
tomy serum prostate specific antigen level. J Urol (2003) 170(2 Pt 1):447–50. 
doi:10.1097/01.ju.0000075351.51838.b3 
39. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. 
Predictors of biochemical outcome with salvage conformal radiotherapy after 
radical prostatectomy for prostate cancer. J Clin Oncol (2003) 21(3):483–9. 
doi:10.1200/JCO.2003.12.043 
40. King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL. Radiotherapy after radical 
prostatectomy: does transient androgen suppression improve outcomes? Int 
J Radiat Oncol Biol Phys (2004) 59(2):341–7. doi:10.1016/j.ijrobp.2003.10.015 
41. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and 
salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat 
Oncol Biol Phys (2003) 56(3):755–63. doi:10.1016/S0360-3016(03)00069-5 
42. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited 
role of radionuclide bone scintigraphy in patients with prostate specific 
antigen elevations after radical prostatectomy. J Urol (1998) 160(4):1387–91. 
doi:10.1016/S0022-5347(01)62545-X 
43. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, De KJ, et  al. 
Predictors of metastatic disease in men with biochemical failure following 
radical prostatectomy. J Urol (2004) 171(6 Pt 1):2260–4. doi:10.1097/01.
ju.0000127734.01845.99 
44. Miralbell R, Vees H, Lozano J, Khan H, Molla M, Hidalgo A, et al. Endorectal 
MRI assessment of local relapse after surgery for prostate cancer: a model 
to define treatment field guidelines for adjuvant radiotherapy in patients at 
high risk for local failure. Int J Radiat Oncol Biol Phys (2007) 67(2):356–61. 
doi:10.1016/j.ijrobp.2006.08.079 
45. Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, et al. [(11)
C]choline PET/CT in prostate cancer patients with biochemical recurrence 
after radical prostatectomy. World J Urol (2009) 27(5):619–25. doi:10.1007/
s00345-009-0371-7 
46. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence 
of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in 
patients with biochemical relapse after radical prostatectomy. J Nucl Med 
(2009) 50(9):1394–400. doi:10.2967/jnumed.108.061507 
47. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et  al. 
Detection of lymph-node metastases with integrated [11C]choline PET/CT 
in patients with PSA failure after radical retropubic prostatectomy: results 
confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol (2007) 
52(2):423–9. doi:10.1016/j.eururo.2007.03.032 
48. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, 
Aschoff P, et al. Histological verification of 11C-choline-positron emission/
computed tomography-positive lymph nodes in patients with biochem-
ical failure after treatment for localized prostate cancer. BJU Int (2008) 
102(4):446–51. doi:10.1111/j.1464-410X.2008.07592.x 
49. Alongi F, Liardo RL, Iftode C, Lopci E, Villa E, Comito T, et al. 11C choline 
PET guided salvage radiotherapy with volumetric modulation arc therapy and 
hypofractionation for recurrent prostate cancer after HIFU failure: prelimi-
nary results of tolerability and acute toxicity. Technol Cancer Res Treat (2014) 
13(5):395–401. doi:10.7785/tcrtexpress.2013.600268 
50. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et  al. 
18F-choline and/or 11C-acetate positron emission tomography: detection of 
residual or progressive subclinical disease at very low prostate-specific antigen 
values (<1 ng/mL) after radical prostatectomy. BJU Int (2007) 99(6):1415–20. 
doi:10.1111/j.1464-410X.2007.06772.x 
51. Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T. Prostate-
specific membrane antigen-based imaging in prostate cancer: impact on 
clinical decision making process. Prostate (2015) 75(7):748–57. doi:10.1002/
pros.22956 
52. Sah BR, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, et  al. 
Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin 
analogue BAY 864367 in patients with prostate cancer. J Nucl Med (2015) 
56(3):372–8. doi:10.2967/jnumed.114.147116 
53. Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P. The 
value of prostate specific antigen and transrectal ultrasound guided biopsy in 
detecting prostatic fossa recurrences following radical prostatectomy. J Urol 
(1993) 149(5):1024–8. 
54. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy 
in detecting local recurrence after radical prostatectomy. Urology (2005) 
66(2):350–5. doi:10.1016/j.urology.2005.03.014 
55. Fiorino C, Foppiano F, Franzone P, Broggi S, Castellone P, Marcenaro 
M, et  al. Rectal and bladder motion during conformal radiotherapy after 
radical prostatectomy. Radiother Oncol (2005) 74(2):187–95. doi:10.1016/j.
radonc.2004.10.002 
56. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, 
et al. Guidelines for target volume definition in post-operative radiotherapy 
for prostate cancer, on behalf of the EORTC Radiation Oncology Group. 
Radiother Oncol (2007) 84(2):121–7. doi:10.1016/j.radonc.2007.07.017 
57. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses 
in localized prostate cancer treatment: a meta-analysis of randomized, con-
trolled trials. Int J Radiat Oncol Biol Phys (2009) 74(5):1405–18. doi:10.1016/j.
ijrobp.2008.10.091 
58. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radio-
therapy after prostatectomy. Int J Radiat Oncol Biol Phys (2008) 71(1):23–7. 
doi:10.1016/j.ijrobp.2007.09.047 
59. Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, et  al. 
Improved toxicity profile following high-dose postprostatectomy salvage 
radiation therapy with intensity-modulated radiation therapy. Eur Urol (2011) 
60(6):1142–8. doi:10.1016/j.eururo.2011.08.006 
60. Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, et al. High-
dose salvage intensity-modulated radiotherapy with or without androgen 
deprivation after radical prostatectomy for rising or persisting  prostate-specific 
antigen: 5-year results. Eur Urol (2011) 60(4):842–9. doi:10.1016/j.eururo.2011. 
04.021 
61. Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Holscher T, Gut P, et al. Acute 
toxicity and quality of life after dose-intensified salvage radiation therapy 
for biochemically recurrent prostate cancer after prostatectomy: first results 
of the randomized trial SAKK 09/10. J Clin Oncol (2015) 33(35):4158–66. 
doi:10.1200/JCO.2015.63.3529 
62. Shipley WU, Seiferheld W, Lukka H, et al. Report of NRG Oncology/RTOG 
9601, a phase III trial in prostate cancer: anti-androgen therapy (AAT) with 
bicalutamide during and after radiation therapy (RT) in patients following 
radical prostatectomy (RP) with pT2-3pN0 disease and an elevated PSA. 
Presented at the American Society of Radiation Oncology (ASTRO) 57th Annual 
Meeting, LBA 5. (2015).
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Herrera and Berthold. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
